Form 4: Amicus Therapeutics Acquired by BioMarin for $14.50/Share

Director Margaret G. McGlynn reports the disposal of all equity holdings following the completed acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc.

Summary

• Director Margaret G. McGlynn disposed of 94,631 shares of common stock at $14.50 per share.
• Multiple tranches of stock options totaling 303,630 shares were cancelled and converted into cash payments based on the $14.50 acquisition price.
• The transaction marks the formal completion of the acquisition of Amicus Therapeutics (FOLD) by BioMarin Pharmaceutical Inc.
• All restricted stock units and stock options held by the director vested in full upon the consummation of the merger.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing confirming the final exit of a director following a completed corporate acquisition.

Positives

• The acquisition provides immediate liquidity to shareholders at a fixed price of $14.50 per share.
• Full vesting of all outstanding restricted stock units and stock options for the director upon merger completion.

Negatives

• The director no longer holds any equity interest in the company following the acquisition.
• The company will cease to exist as an independent publicly traded entity.

Risks

• The company is no longer an independent entity, eliminating future growth potential for current shareholders under the previous corporate structure.

Future Outlook

The company has been acquired by BioMarin Pharmaceutical Inc.; therefore, no further independent forward-looking guidance is provided.

Industry Context

StockSavvy.ai notes that this acquisition represents a significant consolidation in the rare disease and biotechnology sector, as BioMarin absorbs Amicus Therapeutics' portfolio and pipeline.

Comparison to Industry Standards

• The acquisition price of $14.50 per share reflects the final valuation agreed upon by the boards of both companies.
• The full vesting of equity awards upon change-in-control is a standard practice in executive compensation agreements within the biotech industry.

Corporate Governance

Stakeholder Impact

• Shareholders receive cash consideration for their holdings.
• Directors and officers have liquidated their equity positions.

Next Steps

• Delisting of Amicus Therapeutics (FOLD) from public exchanges.

Key Dates

Keywords

Amicus Therapeutics, BioMarin, Merger, Acquisition, FOLD, Insider Transaction, Form 4